| View |
|
DRP-14203-01
|
Clindamycin (as phosphate)
|
Dalasave
|
150 mg/mL (300 mg / 2mL)
|
Solution for Injection (IM/IV)
|
Antibacterial (Lincosamide)
|
Maxitech Pharma (Pvt.) Ltd
|
Pakistan
|
CLIDP Conversion
|
28 March 2024
|
20 July 2028
|
| View |
|
DRP-14215-01
|
Iron (as Iron Sucrose)
|
Ironsave
|
20 mg/mL
|
Solution for injection (IV)
|
Anti-anemic Preparation
|
Maxitech Pharma (Pvt) Ltd.
|
Pakistan
|
CLIDP Conversion
|
17 March 2024
|
27 July 2028
|
| View |
|
DRP-14375-03
|
Dutasteride + Tamsulosin Hydrochloride
|
Dutam
|
500 mcg/400 mcg
|
Capsule
|
Benign Prostatic Hypertrophy Drug (Alpha-adrenoreceptor Antagonist)
|
Pell Tech Healthcare Private Ltd.
|
India
|
CLIDP Conversion
|
25 March 2024
|
31 August 2028
|
| View |
|
DRP-14435
|
Co-Amoxiclav
|
Bactoclav
|
500 mg/125 mg
|
Tablet
|
Antibacterial (Penicillin/Beta-Lactamase Inhibitor)
|
Micro Labs Limited
|
India
|
Automatic Renewal
|
21 March 2024
|
25 January 2029
|
| View |
|
DRP-14484-03
|
Potassium citrate
|
Calta
|
1.620 g (15 mEq)
|
Extended-Release Tablet
|
Antiurolithic
|
Cooper Pharma Limited
|
India
|
CLIDP Conversion
|
10 March 2024
|
12 September 2028
|
| View |
|
DRP-14606-01
|
Apixaban
|
Urania
|
5 mg
|
Film-Coated Tablet
|
Anti-Thrombotic Agent (Direct Factor Xa Inhibitor)
|
Baroque Pharmaceuticals Pvt. Ltd
|
India
|
CLIDP Conversion
|
26 March 2024
|
27 October 2028
|
| View |
|
DRP-14610-01
|
Azithromycin (as dihydrate)
|
None
|
200 mg/ 5 mL
|
Powder for Suspension
|
Antibacterial
|
Fredun Pharmaceuticals Limited
|
India
|
CLIDP Conversion
|
24 March 2024
|
07 April 2027
|
| View |
|
DRP-14620-01
|
Dabigatran Etexilate (as mesylate)
|
Karisa
|
150 mg
|
Capsule
|
Antithrombotic Agent (Direct Thrombin Inhibitor)
|
Globela Pharma Private Limited
|
India
|
CLIDP Conversion
|
17 March 2024
|
14 November 2028
|
| View |
|
DRP-14621-01
|
Dabigatran Etexilate (as mesylate)
|
Karisa
|
110 mg
|
Capsule
|
Antithrombotic Agent (Direct Thrombin Inhibitor)
|
Globela Pharma Private Limited
|
India
|
CLIDP Conversion
|
24 March 2024
|
14 November 2028
|
| View |
|
DRP-14622-01
|
Dabigatran Etexilate (as mesylate)
|
Karisa
|
75 mg
|
Capsule
|
Antithrombotic Agent (Direct Thrombin Inhibitor)
|
Globela Pharma Private Limited
|
India
|
CLIDP Conversion
|
24 March 2024
|
14 November 2028
|
| View |
|
DRP-14634-01
|
Clarithromycin
|
Claritone
|
50 mg/mL (250 mg/5 mL)
|
Powder for Oral Suspension (Raspberry Flavor)
|
Antibacterial (Macrolide)
|
Globela Pharma Private Limited
|
India
|
CLIDP Conversion
|
10 March 2024
|
08 November 2028
|
| View |
|
DRP-14734-01
|
Sertraline
|
Sertrakip
|
50 mg
|
Tablet
|
Antidepressant
|
Micro Labs Limited
|
India
|
CLIDP Conversion
|
09 March 2024
|
10 June 2028
|
| View |
|
DRP-14738-01
|
Quetiapine (as fumarate)
|
Quetigrand 200
|
200 mg
|
Film-Coated Tablet
|
Antipsychotic
|
Magbro Healthcare Pvt. Ltd.
|
India
|
CLIDP Conversion
|
28 March 2024
|
20 December 2028
|
| View |
|
DRP-14739-01
|
Quetiapine (as fumarate)
|
Quetigrand 100
|
100 mg
|
Film-Coated Tablet
|
Antipsychotic
|
Magbro Healthcare Pvt. Ltd.
|
India
|
CLIDP Conversion
|
28 March 2024
|
20 December 2028
|
| View |
|
DRP-14777-01
|
Norepinephrine (as bitartrate)
|
Epinorine 1
|
1 mg/mL (4 mg/4 mL)
|
Solution for Injection (I.V. Infusion)
|
Adrenergic/ Dopaminergic Agent
|
Ultra Laboratories Private Limited
|
India
|
CLIDP Conversion
|
25 March 2024
|
03 January 2029
|
| View |
|
DRP-14855-01
|
Polyethylene Glycol + Glycerin + Hypromellose
|
ICARE
|
10 mg/2 mg/2 mg per mL
|
Ophthalmic Solution (Eye Drops)
|
Ophthalmic Lubricant
|
Hanlim Pharmaceutical Co., Ltd.
|
Korea
|
CLIDP Conversion
|
24 March 2024
|
01 February 2029
|
| View |
|
DRP-14858-01
|
Paracetamol
|
Parazamil
|
10 mg/mL
|
Solution for Injection (IV)
|
Analgesic/Antipyretic
|
Shijiazhuang No. 4 Pharmaceutical Co., Ltd.
|
China
|
CLIDP Conversion
|
24 March 2024
|
22 December 2028
|
| View |
|
DRP-1617-05
|
Ampicillin (as sodium)
|
Amzellin-500
|
500 mg
|
Powder for Injection (IM/IV)
|
Antibacterial (Penicillin with extended spectrum)
|
Inject Care Parenterals Pvt. Ltd
|
India
|
Renewal
|
25 July 2024
|
03 September 2029
|
| View |
|
DRP-1646-11
|
Salbutamol (as sulfate) + Guaifenesin
|
Asvent Plus
|
1 mg/ 50 mg per 5 mL
|
Syrup
|
Beta-2-Adrenoreceptor Agonist/Expectorant
|
Lloyd Laboratories, Inc
|
Philippines
|
CLIDP Conversion
|
17 March 2024
|
12 March 2026
|
| View |
|
DRP-1651-07
|
FOLIC ACID
|
Zeofol
|
5 mg
|
Tablet
|
Vitamin/Hematinic
|
LifeSquare Laboratories Inc.
|
Philippines
|
Renewal
|
19 May 2024
|
25 September 2029
|